News & Updates
Showing Multidisciplinary articles
Showing
Osimertinib after CRT safe, effective in unresectable stage III EGFR-mutated NSCLC
Treatment with osimertinib following definitive chemoradiotherapy (CRT) demonstrates a manageable safety profile in patients with unresectable stage III EGFR-mutated nonsmall cell lung cancer (NSCLC), reports a study presented at WCLC 2024.
Osimertinib after CRT safe, effective in unresectable stage III EGFR-mutated NSCLC
07 Oct 2024
New model predicts HCC risk in noncirrhotic CHB patients
A novel prognostic model based on the viral loads of hepatitis B virus (HBV) demonstrates its utility in predicting and stratifying the risk of hepatocellular carcinoma (HCC) in noncirrhotic patients with chronic hepatitis B (CHB) who are not yet receiving antiviral therapy.
New model predicts HCC risk in noncirrhotic CHB patients
07 Oct 2024
Darolutamide + ADT, without docetaxel, shows efficacy benefits in mHSPC
Darolutamide plus androgen-deprivation therapy (ADT), without docetaxel, improves radiological progression-free survival (rPFS) and secondary efficacy outcomes vs placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to results of the global phase III ARANOTE trial presented at ESMO 2024.
Darolutamide + ADT, without docetaxel, shows efficacy benefits in mHSPC
07 Oct 2024
Aspirin may improve survival in PIK3CA-mutated colon cancer
Adjuvant treatment with aspirin appears to provide some protection in patients with resected, PIK3CA-mutant stage II and III colon cancer, demonstrating a clinically significant improvement (43 percent) in disease-free survival (DFS), suggests a study presented at ESMO Congress 2024.
